The cannabis stocks we’ve weeded out could get a big boost from being included in the HMMJ ETF after the recent rebalancing
SmallCapPower | July 9, 2019: On July 3, Horizons completed its quarterly rebalance of the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ). In the recent rebalancing, the ETF expanded to include 10 more companies. Today we have picked out four cannabis stocks that were added to the HMMJ that could benefit most from this inclusion.
*Share prices as at close Friday, July 5, 2019, data obtained from S&P Capital IQ
Pyxus International Inc. (NYSE:PYX) – $15.36
Tobacco & Cannabis
Pyxus International is a global merchant of leaf tobacco to cigarette manufacturers, and most recently entered the Canadian cannabis business. The Company sources flue-cure, burley, and oriental tobacco from growers around the world either directly or via auction. The Company’s three largest customers are Philip Morris International, China Tobacco International, and Imperial Brands PLC. Pyxus operates in the cannabis space through its wholly-owned subsidiary FIGR Inc, a vertically-integrated legal cannabis company headquartered in Toronto, Ontario.
- Market Cap: $139.7M
- YTD Return: 21.4%
- 90 Day Average Trading Volume: 650,000
- Shares Outstanding: 9.1M
Abacus Health Products Inc. (CSE:ABCS) – $9.75
Abacus Health Products develops and commercializes over-the-counter topical pain relief and therapeutic skincare products. The products contain all-natural, organic, and active pharmaceutical ingredients and are infused with hemp-derived CBD. All the Company’s products are OTC FDA-registered and are able to make health claims. On July 2, Abacus Health Products announced that its shares have begun trading on the OTCQX Market under the symbol ABAHF.
- Market Cap: $210.7M
- YTD Return: -2.5%
- 90 Day Average Trading Volume: 40,000
- Shares Outstanding: 21.6M
Cardiol Therapeutics Inc. (TSX:CRDL) – $4.55
Cardiol Therapeutics is a biotechnology company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure. Cardiol has been able to differentiate itself from other CBD companies by focusing on the production of CBD through a chemical synthesis process, an advanced method of extraction. On June 20, Cardiol Therapeutics Inc announced that it is planning an international clinical trial in acute myocarditis, a condition characterized by the inflammation of the heart.
- Market Cap: $117.7M
- YTD Return: 5.8%
- 90 Day Average Trading Volume: 80,000
- Shares Outstanding: 25.9M
cbdMD Inc. (AMEX:YCBD) – $5.21
cbdMD produces and distributes various CBD products in the United States. The Company operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD products under the cbdMD brand. The Licensing segment establishes brands through licensing of select products that focus on health and wellness. YCBD’s Entertainment segment produces and markets various entertainment distribution platforms under the EE1 brand.
- Market Cap: $144.4M
- YTD Return: 65.4%
- 90 Day Average Trading Volume: 280,000
- Shares Outstanding: 27.7M
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: